Discover and read the best of Twitter Threads about #liquidbiopsies
Most recents (4)
Welcome to #TumorBoardTuesday
Hello Everyone,
I’m Manju George, a stage 3b rectal cancer survivor
I was diagnosed in 2017 & I wasn’t yet 45 then
Are you excited to discuss #CtDNA testing?
Let's get started..
But first things 1st
Tell us about you
#PatientExperience #CRCSM
Hello Everyone,
I’m Manju George, a stage 3b rectal cancer survivor
I was diagnosed in 2017 & I wasn’t yet 45 then
Are you excited to discuss #CtDNA testing?
Let's get started..
But first things 1st
Tell us about you
#PatientExperience #CRCSM
My tumor
-In the upper rectum near the recto-sigmoid
Clean CAP CT scan & MRI pelvis
CEA 1.0 at dx
LAR sx 1st
Stage 3b rectal, MSS, BRAF WT
No chemo-RT
4 cycles of CAPOX
Clean scans at the end of treatment🎉🎉
What about you?
#TumorBoardTuesday #CRCSM #CtDNA #LiquidBiopsies
-In the upper rectum near the recto-sigmoid
Clean CAP CT scan & MRI pelvis
CEA 1.0 at dx
LAR sx 1st
Stage 3b rectal, MSS, BRAF WT
No chemo-RT
4 cycles of CAPOX
Clean scans at the end of treatment🎉🎉
What about you?
#TumorBoardTuesday #CRCSM #CtDNA #LiquidBiopsies
Survivorship--Different parts, very nice diagram from @CancerSurvSM
Great patient worksheet resource here--smhs.gwu.edu/cancercontrolt…
#TumorBoardTuesday #PatientExperience #CtDNA
Great patient worksheet resource here--smhs.gwu.edu/cancercontrolt…
#TumorBoardTuesday #PatientExperience #CtDNA
#GI21 time for another #Tweetorial🧵 on
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
🧵2️⃣ #GI21
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
🧵3️⃣ #GI21
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
0/6
Background: Liquid biopsies have the potential to become an invaluable tool in the management of #cancer.
That’s why, it is important to generate solid evidence to define areas in which they can guide treatment decisions.
@OncoAlert 🚨 #LiquidBiopsies #PrecisionMedicine
Background: Liquid biopsies have the potential to become an invaluable tool in the management of #cancer.
That’s why, it is important to generate solid evidence to define areas in which they can guide treatment decisions.
@OncoAlert 🚨 #LiquidBiopsies #PrecisionMedicine
1/6
Accordingly, this paper by @LizzySmyth1 & team in @myESMO @Annals_Oncology on the prognostic value of longitudinal ctDNA 🧬💉 assessment in #EsophagealCancer #esocsm addresses a very relevant question.
@OncoAlert 🚨 #PrecisionMedicine #LiquidBiopsies
annalsofoncology.org/article/S0923-…
Accordingly, this paper by @LizzySmyth1 & team in @myESMO @Annals_Oncology on the prognostic value of longitudinal ctDNA 🧬💉 assessment in #EsophagealCancer #esocsm addresses a very relevant question.
@OncoAlert 🚨 #PrecisionMedicine #LiquidBiopsies
annalsofoncology.org/article/S0923-…
2/6
✅ 97 patients that underwent neo-adjuvant chemotherapy & resection with a total of 245 available samples were identified in 🇬🇧 OCCAMS consortium dataset.
✅ Samples were analysed w a pan #cancer ctDNA panel
@OncoAlert 🚨
✅ 97 patients that underwent neo-adjuvant chemotherapy & resection with a total of 245 available samples were identified in 🇬🇧 OCCAMS consortium dataset.
✅ Samples were analysed w a pan #cancer ctDNA panel
@OncoAlert 🚨
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
